Natera (NTRA) Stock: Price, Trend, Options & Financials
Natera's price regime, relative strength, unusual-options and unusual-volume history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
NTRA closed at $332.03 on Aug 21, 2026. The price is +21.8% from its 50-day average and +44.8% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +63.0%, beating SPY by 59.9%. It remains 0.5% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is +21.8% from its 50-day average and +44.8% from its 200-day average. Over three months, NTRA returned +63.0% versus +3.1% for SPY.
- vs 50-day
- +21.8%
- vs 200-day
- +44.8%
- From 52W high
- -0.5%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
NTRA appeared in a UOA top-30 list on 2 of 62 archived scanner sessions: 2 call-side, 0 put-side and 0 on both lists. The latest session did not place it in either top 30. Its larger composite score was 0.48, below the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-06-29 | #8 | — |
| 2026-06-25 | #29 | — |
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.716 calls, 0.164 puts.
Curated-manager ownership
2 of the 20 managers in the project's curated 13F set reported a long Natera position in their latest filing, worth $868M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Duquesne Family Office Stanley Druckenmiller · NTRA | $865M | 16.60% | 3.19M | +4.0% increased | 2026-06-30 |
Baron Capital Group Ron Baron · NTRA | $3M | 0.00% | 10,238 | -38.5% reduced | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open NTRA Financials →How NTRA trades — the working manual
Natera develops and commercializes genetic tests in women's health, oncology and organ health. For the stock, test volume and reimbursement must translate into durable revenue growth and cash generation, while clinical evidence, coverage decisions and legal or regulatory outcomes shape the value of each franchise.
What can move the tape
- 01Test volumes and average selling prices across Panorama, Signatera and Prospera.
- 02Coverage expansion, reimbursement, collections and the conversion of reported tests into revenue.
- 03Clinical evidence and adoption in minimal residual disease, transplant monitoring and reproductive health.
- 04Gross margin, expense growth and cash generation as laboratory capacity and commercial spending scale.
What can fool the read
- 01Reimbursement decisions and billing or collections can cause revenue per test to change independently of volume.
- 02Competing diagnostics, clinical evidence or guideline changes can slow adoption in key indications.
- 03Regulatory, legal and compliance matters can create costs or change commercialization assumptions.
- 04A valuation built on sustained growth can react sharply to test-volume, pricing or margin disappointments.
Natera triggered 3 issuer-level flags in the committed 2026-04-01–2026-08-21 archive. The latest was NTRA on 2026-06-24: 2.0× its 30-day average volume while the stock moved +7.0% that session.
Not published yet. The local archive has 0 reported NTRA events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-22 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
NTRA stock questions
Is NTRA stock in an uptrend?+
NTRA is classified in the “established uptrend” regime as of 2026-08-21: the close is +21.8% from its 50-day average and +44.8% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in NTRA mean?+
Natera's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the NTRA 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are NTRA's income statement and cash flow?+
The dedicated NTRA Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no NTRA earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.